Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

Study Status

Open to Enrollment

Study Description

This clinical trial is for people diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET) who are either:

  • refractory or intolerant to the drug hydroxyurea or
  • have suffered a Splanchnic Vein Thrombosis

The purpose of the study is to determine the effectiveness of treating people with ET and PV with aspirin and Pegylated Interferon Alfa-2a instead of the standard treatment hydrooxyurea, because the standard treatment may not be suitable for them.

Pegylated Interferon Alfa-2a is a type of interferon, which is a form of a hormone produced naturally in the blod which reduces the production of blood cells. It has been shown to reduce the amount of a protein thought to be involved in causeing ET and PV. Pegylated Interferon Alfa-2a will be given by a subcutaneous injection every week.

Disease Status and/or Stage

High Risk Polycythemia Vera; High Risk Essential Thrombocythemia


Myeloproliferative Disorders-Research Consortium

Key Eligibility

  • Diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET)
    • High Risk Disease
      • Age >60
      • Intolerant or resistant to hydroxyurea
    • Have Splanchnic Vein Thrombosis (SVT)
      • Age 18 and older
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Richard Silver, MD


Protocol ID

MPD-RC 111

Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page